Diet for Hypoglycemia - Hypoglycemia Treatment News

Hypoglycemia Treatment News

GlucaGen medical kits recalled Wednesday, August 25, 2010 @ 12:39PMAn emergency kit used for the treatment of severe hypoglycemia in people with diabetes has been recalled because of a manufacturing defect.
MannKind Corporation Providing AFREZZA™ To Juvenile Diabetes Research Foundation For Artificial Pancreas Project Wednesday, August 25, 2010 @ 6:49AMMannKind Corporation (Nasdaq: MNKD) announced that the company will supply its novel, ultra rapid acting insulin AFREZZATM (insulin human [rDNA origin]) for use in a study being conducted by the Juvenile Diabetes Research Foundation (JDRF) as part of its Artificial Pancreas Project. The planned two-year study in patients with type 1 diabetes will leverage the unique rapid action of AFREZZA for ...
Wireless sensor for diabetics Thursday, July 29, 2010 @ 1:38AMWASHINGTON - RESEARCHERS have developed an implantable sensor that measures blood sugar continuously and transmits the information without wires - a milestone, they said, in diabetes treatment. The device worked in one pig for more than a year and in another for nearly 10 months with no trouble, they reported in the journal Science Translational Medicine.
Encouraging Data on MNKD's Afrezza Wednesday, June 30, 2010 @ 8:10AMMNKD's inhaled insulin prospect Afrezza, generates encouraging data.
Insulin pump better than injections Wednesday, June 30, 2010 @ 6:44AMinsulin pump is better than multiple daily injections of the medication in controlling blood glucose levels in patients with Type 1 diabetes, a new study finds.
Medtronic's sensor-augmented insulin pump therapy provides superior glucose control, confirms STAR 3 study Wednesday, June 30, 2010 @ 4:24AMIn the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections (MDI), the most common approach to care today.
Better Glucose Control Achieved With Medtronic's Sensor-Augmented Insulin Pump Therapy Than Daily Insulin Injections ... Tuesday, June 29, 2010 @ 1:32PMAdults and children with diabetes who used the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without hypoglycemia increase compared to patients using multiple daily insulin injections, in the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes. According to the data, there was a statistically significant drop ...
Sensor and insulin pump results in better blood-sugar control in all age groups with diabetes Tuesday, June 29, 2010 @ 11:11AMAdding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.
Insulin Pump with Blood Sugar Sensor May Improve on Injections Tuesday, June 29, 2010 @ 11:04AMTUESDAY, June 29 (HealthDay News) -- Type 1 diabetics who used an insulin pump and a sensor that continuously monitored their blood sugar levels had better control over their illness than people taking insulin injections, a large clinical trial finds.
Medtronic Initiates Diabetes Study Tuesday, June 29, 2010 @ 10:08AMMedtronic initiated patient enrollment for a study to evaluate the effectiveness of one of its diabetes management devices.
Marcadia And Lilly Sign Development, License Agreement For Novel Glucagon Program In Severe Hypoglycemia Tuesday, June 29, 2010 @ 9:28AMMarcadia Biotech, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe hypoglycemia.
For Type 1 Diabetics, Pump Therapy With Continuous Glucose Monitoring Is Better Than Daily Injections Tuesday, June 29, 2010 @ 7:40AMA year-long clinical trial by Yale University and other institutions showed that treatment with sensor-augmented insulin pumps, which include a system of continuous glucose monitoring, leads to significantly greater control of type 1 diabetes than a daily regimen of multiple insulin injections. Results of the STAR 3 trial were presented at the annual meeting of the American Diabetes Association ...
STAR 3 Trial Results Confirm Medtronic's Sensor-Augmented Insulin Pump Therapy Achieves Better Glucose Control Than ... Tuesday, June 29, 2010 @ 7:00AMMINNEAPOLIS----In the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections , the most common approach to care today.
Coinjection Of Halozyme's RHuPH20 Enzyme Accelerates The Absorption And Action Of Mealtime Insulin Analogs Tuesday, June 29, 2010 @ 6:51AMHalozyme Therapeutics, Inc. (Nasdaq: HALO) announced clinical trial results showing that the addition of its proprietary rHuPH20 (recombinant human hyaluronidase, PH20) enzyme to three different mealtime insulin analogs accelerated their absorption. The acceleration produced by the coadministration of rHuPH20 produced significantly more pronounced insulin effects during the first hour after ...
Study Shows Gradual Addition Of NovoLog® At Mealtime Can Reduce A1c In Type 2 Diabetes Patients Tuesday, June 29, 2010 @ 6:50AMNovo Nordisk announced results of its STEPwise™ trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, presented at the American Diabetes Association (ADA) 2010 Scientific Sessions, demonstrated a reduction of A1c levels in type 2 diabetes patients when a dose of NovoLog® was introduced at meals, using two approaches ...
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared To Placebo In ... Tuesday, June 29, 2010 @ 6:49AMData from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose (PPG).(1,2) Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 (DPP-4) inhibitor as an oral once-daily ...
Study, Popular Diabetes Medications Not Associated With Increased Risk Of Acute Pancreatitis Tuesday, June 29, 2010 @ 6:49AMTwo popular diabetes drugs do not increase the risk of acute pancreatitis, according to a study presented today at the American Diabetes Association's (ADA's) 70th Scientific Sessions. The study conducted by Medco Health Solutions, Inc. (NYSE: MHS) in association with the Medco Research Institute™ and the University of Texas Southwestern Medical School examined the relationship between Byetta® ...
AFREZZA Demonstrates Long-Term Efficacy in Controlling Blood Sugar Levels in Patients with Type 2 Diabetes Monday, June 28, 2010 @ 5:30PMORLANDO, Fla.----AFREZZATM Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented today at the ...
Coinjection of Halozyme's rHuPH20 Enzyme Accelerates the Absorption and Action of Mealtime Insulin Analogs Monday, June 28, 2010 @ 5:16PMSAN DIEGO, June 28 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced clinical trial results showing that the addition of its proprietary rHuPH20 (recombinant human hyaluronidase, PH20) enzyme to three different mealtime insulin analogs accelerated their absorption. The acceleration produced by the coadministration of rHuPH20 produced significantly more ...
Study Shows Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients Monday, June 28, 2010 @ 2:45PMORLANDO, Fla., June 28 /PRNewswire-FirstCall/ -- Today Novo Nordisk announced results of its STEPwise(TM) trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, presented at the American Diabetes Association (ADA) 2010 Scientific Sessions, demonstrated a reduction of A1c levels in type 2 diabetes patients when a dose ...
New Data Demonstrates Victoza(R) Provided Superior And Sustained Blood Sugar Control And Weight Reduction Compared To ... Monday, June 28, 2010 @ 1:17PMLate-breaking Novo Nordisk (NYSE: NVO) extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia® plus metformin at 52 weeks. Key findings from the study include ...
Study Shows Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients Monday, June 28, 2010 @ 11:00AMToday Novo Nordisk announced results of its STEPwiseâ¢ trial, which identified a method of intensifying insulin treatment with NovoLogÂ® . The study, presented at the American Diabetes Association 2010 Scientific Sessions, demonstrated a reduction of A1c levels in type 2 diabetes patients when a dose of NovoLogÂ® was introduced at meals, using two approaches that start with the largest meal of ...
Study: Popular Diabetes Medications Not Associated With Increased Risk of Acute Pancreatitis Monday, June 28, 2010 @ 9:17AMFRANKLIN LAKES, N.J., June 28 /PRNewswire-FirstCall/ -- Two popular diabetes drugs do not increase the risk of acute pancreatitis, according to a study presented today at the American Diabetes Association's (ADA's) 70th Scientific Sessions. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100609 ...
Marcadia and Lilly Sign Development, License Agreement for Novel Glucagon Program in Severe Hypoglycemia Monday, June 28, 2010 @ 9:16AMINDIANAPOLIS, June 28 /PRNewswire-FirstCall/ -- Marcadia Biotech, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe ...
Merck: Data Show Januvia Outperforms Pfizer's Glucotrol Monday, June 28, 2010 @ 8:46AMMerck: Data Show Januvia Outperforms Pfizer's Glucotrol
Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial Monday, June 21, 2010 @ 2:13AMAHMEDABAD, India, June 21, 2010 /PRNewswire/ -- Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist.
Amylin Pharmaceuticals To Present New Data And Insights From The Company's Diabetes Programs At ADA 2010 Saturday, June 19, 2010 @ 6:17AMAmylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON™ (exenatide extended-release for injectable suspension) at the American Diabetes Association's (ADA's) 70th Annual Scientific Sessions being ...
DURATION-4 Study Results: BYDUREON Efficacy And Tolerability Profile Extended To Monotherapy Treatment Saturday, June 19, 2010 @ 6:15AMAmylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON™ (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications...
Forest Laboratories and TransTech Pharma Enter Into License Agreement for the Development and Commercialization of ... Tuesday, June 15, 2010 @ 3:44AMHigh Point, NC and New York, NY, June 8, 2010: TransTech Pharma, Inc and Forest Laboratories, Inc. (NYSE: FRX), today announced that TransTech Pharma and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. have entered into a license agreement for the development and commercialization of small molecule compounds discovered and developed by TransTech Pharma.
Louisville news: Culture wars, 1964 revisited edition [News roundup] Friday, May 21, 2010 @ 8:13AMread more
Death prompts change to DGH care of patients with diabetes Thursday, May 6, 2010 @ 2:20AMCHANGES have been made to the care of diabetic patients at the DGH following the death of an Eastbourne woman from a suspected heart failure. (05/05/2010 08:34:41)
Insulin in a Pill Tuesday, May 4, 2010 @ 11:26PMA drugmaker is testing an alternative to diabetes injections, but many sizable hurdles remain. Late last year, Denmark-based Novo Nordisk quietly started phase 1 clinical trials of a pill that it hopes to market as an alternative to insulin injections. Offering patients with diabetes the chance to avoid painful needles has long been the holy grail of some pharmaceutical companies, especially ...
Definitive Diabetes Indicator Deceptively High In African-American Children Tuesday, May 4, 2010 @ 5:20PMRacial disparities could result in life-threatening hypoglycemia and increased complicationsResearchers at LSU Health Sciences Center New Orleans and Children's Hospital of New Orleans have found that there is a major difference in the hemoglobin A1c (HbA1c) response to blood glucose between African-American and Caucasian children with diabetes.
Tight Glycemic Control in Critically Ill Patients [Letters] Tuesday, May 4, 2010 @ 3:37PMTo the Editor: Recently published trials 1-2 of tight glycemic control in critically ill patients have documented lack of treatment benefit and frequent severe hypoglycemia.
Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON(TM) Thursday, April 22, 2010 @ 6:42PMSAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., April 22, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc.
Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON Thursday, April 22, 2010 @ 4:15PMSAN DIEGO, INDIANAPOLIS & WALTHAM, Mass.----Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S.
Phoenix VA Health Care System (PVAHCS) Researcher, Dr. William Duckworth Will Receive First Ever Barnwell Award Tuesday, April 20, 2010 @ 5:15PMPHOENIX, April 20 /PRNewswire-USNewswire/ -- As a leader in Clinical Diabetes Research, Dr.
Phoenix VA Health Care System (PVAHCS) Researcher, Dr. William Duckworth Will Receive First Ever Barnwell Award Tuesday, April 20, 2010 @ 2:07PMPHOENIX, April 20 /PRNewswire-USNewswire/ -- As a leader in Clinical Diabetes Research, Dr. William Duckworth will receive the Barnwell Award April 22 at 1:15 p.m., VA Central Office Auditorium, 2nd floor, Room 230, 810 Vermont Ave NW, DC.
Dogs helping scientists find cures for serious diseases Saturday, April 17, 2010 @ 7:58PMThey keep us company, make us smile and are always there to lend a furry paw, but could dogs do even more?
Drill Gives Nursing Students Hands-On Experience Wednesday, April 14, 2010 @ 4:41PMWith natural disasters around the world, nurses called in to help are forced to make life and death decisions on the spot.
Birth Weight And Type 2 Diabetes, UK Thursday, April 8, 2010 @ 9:40PMAn international team of researchers have found a genetic link between low birth weight and the risk of going on to develop Type 2 diabetes in later life. The team analysed over 38,000 Europeans from 19 studies of pregnancy and birth and found that two genetic variants showed strong associations with birth weight. The discovery could well lead to a deeper understanding of how to manage growth ...
AstraZeneca, US company launch anti-diabetes drug Thursday, April 1, 2010 @ 3:34PMIn an effort to grab a bite of the Rs 2,000-crore anti-diabetes market in India, UK drugmaker AstraZeneca and US pharma firm Bristol-Myers Squibb on Thursday jointly launched the oral drug Onglyza.
BMS, AstraZeneca team-up to launch saxagliptin for Type 2 diabetes in India Thursday, April 1, 2010 @ 4:51AMBristol-Myers Squibb India and AstraZeneca Pharma India Ltd. today announced an alliance to develop and commercialize two compounds for the treatment of type 2 diabetes. Both compounds were discovered by Bristol-Myers Squibb.
GP Groups Disappointed With Lack Of Consultation Over Policy For Patients With Diabetes, Australia Wednesday, March 31, 2010 @ 7:18PMThe members of United General Practice Australia are disappointed that our organisations were not consulted by the Federal Government on today's announcement in relation to proposed changes in arrangements for patients with diabetes. United General Practice Australia calls on the Government to consult with our organisations as a matter of urgency. Immediate engagement with the profession is ...
I, caregiver: Healing in comfort and love Saturday, March 27, 2010 @ 5:38AMHOME-nursing is not the same as a nursing home. Contrary to what was printed in my column last week, my family did not send our mother to a nursing home. Just the thought of it would have traumatised her.
Oxford Area Insulin Pump Users Support Group to hear from expert Thursday, March 25, 2010 @ 12:07PMThe Oxford Area Insulin Pump Users Support Group will meet at 7 p.m. Thursday, April 1 in the LCNB Bank Community Room.
Frost & Sullivan Recognizes MannKind With 2010 North America Entrepreneurial Company of the Year Award Wednesday, March 24, 2010 @ 6:45AMBased on its recent analysis of the pharmaceuticals and biotechnology market, Frost & Sullivan recognizes MannKind Corporation with the 2010 North America Frost & Sullivan Entrepreneurial Company of the Year Award.
Salsalate Seems Effective for Type 2 Diabetes Wednesday, March 24, 2010 @ 3:43AMInvestigators for the Treating Inflammation Using Salsalate in Type 2 Diabetes (TINSAL-T2D) Study Team recruited patients with type 2 diabetes who were treated with diet, exercise, and oral medications at stable doses for at least 8 weeks.
Nod given for new drug to control Type 2 diabetes Tuesday, March 23, 2010 @ 9:36PMJanuvia (sitagliptin), a new oral diabetes drug, has been approved by China's State Food and Drug Administration (SFDA) for distribution in the Chinese market. Pan Changyu, a well-established endocrinologist with the Beijing-based General Hospital of the Chinese People's Liberation Army, said the drug, developed by pharmaceutical giant Merck & Co Inc, is the first approved in a new class of so ...
2010 V Foundation Comeback Award Finalists Announced Tuesday, March 23, 2010 @ 6:30PMCary, N.C. -- The V Foundation for Cancer Research has announced the finalists for the tenth annual V Foundation Comeback Award . The award is presented in conjunction with ESPN and the recipient will be announced March 30 during ESPN’s basketball coverage.